# A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00528697** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 278 (actual)

## Conditions studied

- Attention-Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** ABT-089
- **DRUG:** atomoxetine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00528697
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2013-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00528697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00528697, "A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00528697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*